<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Reperfusion injury of the heart
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Reperfusion injury of the heart
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Reperfusion injury of the heart
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            C Michael Gibson, MS, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Derek M Yellon, PhD, DSc, Hon FRCP, FACC, FESC
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Derek J Hausenloy, MD, PhD, FRCP, FACC, FESC
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Todd F Dardas, MD, MS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 14, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Myocardial injury in the setting of an acute myocardial infarction (MI) is the result of ischemic and reperfusion injury. Reperfusion therapies, including primary percutaneous coronary intervention and fibrinolytic therapy, promptly restore blood flow to ischemic myocardium and limit infarct size.
        </p>
        <p>
         Paradoxically, however, the return of blood flow can result in additional cardiac damage and complications; this is referred to as reperfusion injury [
         <a href="#rid1">
          1-3
         </a>
         ]. Effective therapies to reduce or prevent reperfusion injury have proven elusive. Despite an improved understanding of the pathophysiology of this process and encouraging preclinical trials of multiple agents, most of the clinical trials to prevent reperfusion injury have been disappointing [
         <a href="#rid4">
          4-6
         </a>
         ]. Despite these problems, adjunctive therapies to limit reperfusion injury remain an active area of investigation.
        </p>
        <p>
         This topic will discuss the pathophysiology and manifestations of reperfusion injury, as well as potential therapeutic strategies. The impact of the initial ischemic insult is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1472.html" rel="external">
          "Approach to the patient with suspected angina pectoris", section on 'Pathophysiology'
         </a>
         .)
        </p>
        <p>
         General discussions of the use of reperfusion therapy in acute MI are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/72.html" rel="external">
          "Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/55.html" rel="external">
          "Acute ST-elevation myocardial infarction: The use of fibrinolytic therapy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          DEFINITION
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the first stage of acute MI, myocardial cells are injured as the result of anoxia and the absence of new essential metabolic substrate. In the absence of reperfusion, and in the absence of an adequate collateral circulation, these injured cells die and scar tissue is formed.
        </p>
        <p>
         In the presence of reperfusion, either spontaneous or consequent to reperfusion therapy, ischemic injury is halted but additional injury occurs as the result of reperfusion. Reperfusion injury is characterized by myocardial, vascular, or electrophysiological dysfunction that is induced by the restoration of blood flow to previously ischemic tissue.
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          PATHOPHYSIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         When blood flow to cardiac myocytes is disrupted by occlusion of a coronary artery, a series of events is set in motion that results in cellular injury and death (termed acute ischemic injury). These processes are related to energy production and utilization and include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reduced energy production with a fall in intracellular
         <a class="drug drug_general" data-topicid="9359" href="/z/d/drug information/9359.html" rel="external">
          adenosine
         </a>
         triphosphate (ATP) levels
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A transition from aerobic to anaerobic energy utilization
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An accumulation of the products of anaerobic metabolism
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sodium and calcium overload and reduced intracellular pH
        </p>
        <p>
        </p>
        <p>
         These phenomena lead to dramatic distortions in myocyte physiology and architecture, including mitochondrial and sarcolemmal injury and alterations in intracellular calcium handling. Four important adverse intracellular events are opening of the mitochondrial permeability transition pore, rapid normalization of pH, intracellular calcium overload, and generation of reactive oxygen species [
         <a href="#rid7">
          7-9
         </a>
         ].
        </p>
        <p>
         Initially, the damage is reversible, and restoration of blood flow during this period will lead to recovery of normal structures and function. However, if ischemia persists for an extended period of time, this damage becomes irreversible and cell death occurs.
        </p>
        <p>
         Prior to cell death there is a period during in which the ischemic myocyte is viable but vulnerable to further injury if blood flow is restored (ie, reperfusion injury). Restoration of blood flow is associated with three events that may further injure myocytes:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Microvascular obstruction
         </strong>
         – Although reperfusion removes obstruction to flow in the epicardial circulation, distal flow may remain significantly impaired due to (microvascular) obstruction to flow in small arterial vessels; obstruction may be due to:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Embolization of clot or plaque material from the original site of obstruction.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Formation of new thrombus due to intravascular activation of platelets, complement, and circulating leukocytes.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         External compression of the small vessels due to interstitial edema consequent to a leaky endothelium (endothelial damage).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Direct cellular toxicity.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Vasoconstriction.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Preservation of the coronary microvasculature is essential to the ultimate recovery of myocardial function [
         <a href="#rid10">
          10
         </a>
         ]. Microvascular dysfunction, or the "no reflow" phenomenon, refers to the impairment of resting blood flow within the postischemic vasculature. The clinical significance of microvascular dysfunction lies in its association with worse cardiovascular outcomes [
         <a href="#rid11">
          11
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/81.html" rel="external">
          "Suboptimal reperfusion after primary percutaneous coronary intervention in acute ST-elevation myocardial infarction", section on 'No reflow'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Damage due to local factors –
         </strong>
         Red blood cell deposits (hemorrhage) or local inflammation can further damage the microcirculation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Myocardial edema
         </strong>
         (intracellular and interstitial) occurs in a bimodal pattern after reperfusion. The first wave occurs soon after reperfusion and abates within days; the second wave that starts days later and is associated with healing [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Some of these factors act through mechanisms discussed below.
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Myocyte hypercontracture
         </span>
         <span class="headingEndMark">
          —
         </span>
         Restoration of blood flow to previously ischemic cells can result in myocyte hypercontracture and resultant contraction band necrosis [
         <a href="#rid13">
          13
         </a>
         ]. Factors that contribute to hypercontracture include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increased intracellular calcium – During an ischemic period, intracellular calcium increases due to impaired calcium cycling and sarcolemmal damage [
         <a href="#rid14">
          14
         </a>
         ]. This process can be exacerbated with reperfusion. The restoration of a normal extracellular pH after reperfusion produces a hydrogen gradient across the cell membrane. The sodium/hydrogen (Na/H) exchanger is activated and causes a net influx of sodium into the cytosol. Under normal conditions, the resulting increase in intracellular sodium would be corrected by the sodium/potassium (Na/K) ATPase. However, this channel may not function normally after a period of ischemia due to a lack of energy and structural damage. In this setting, the sodium excess causes the sodium/calcium (Na/Ca) channel to run in reverse, producing an influx of calcium into the already calcium-overloaded cell.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reoxygenation and reenergization of the myocyte – Return of blood flow provides oxygen and energy that stimulates myofibrils, and, in the setting of increased calcium, contraction is uncontrolled and excessive.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Restoration of normal acid-base status – Reduced cytosolic pH during ischemia inhibits myofibrillar contraction [
         <a href="#rid15">
          15
         </a>
         ]. With restoration of blood flow, a normal pH is rapidly restored in the extracellular and then the intracellular space, removing the acidic inhibition to contraction.
        </p>
        <p>
        </p>
        <p>
         Mechanisms by which hypercontracture can result in additional cardiac injury include the following [
         <a href="#rid16">
          16
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cytoskeletal elements can be significantly damaged, ultimately resulting in cell death.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Myocytes tearing away from the tight intercellular junctions during hypercontracture can cause damage to the sarcolemma of adjacent cells.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Oxygen and other free radicals
         </span>
         <span class="headingEndMark">
          —
         </span>
         Free radicals are produced within minutes of reperfusion and continue to be generated for hours after the restoration of blood flow to ischemic tissue [
         <a href="#rid17">
          17
         </a>
         ]. These include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Superoxide anion (O
         <sub>
          2
         </sub>
         <sup>
          -
         </sup>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hydrogen peroxide (H
         <sub>
          2
         </sub>
         O
         <sub>
          2
         </sub>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypochlorous acid (HOCl)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nitric oxide-derived peroxynitrite
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hydroxyl radical (OH
         <sup>
          -
         </sup>
         )
        </p>
        <p>
        </p>
        <p>
         Several mechanisms have been proposed for the development of these free radicals including xanthine oxidase, activated neutrophils, electron leakage from ischemic mitochondrion, catecholamine oxidation, as well as cyclooxygenase and lipoxygenase enzymes [
         <a href="#rid18">
          18
         </a>
         ]. The relative importance of each of these pathways is not clear, but they are probably interrelated and may potentiate one another.
        </p>
        <p>
         Free radicals damage myocytes directly by altering membrane proteins and phospholipids [
         <a href="#rid19">
          19
         </a>
         ]. Because these membrane constituents play crucial roles as receptors, enzymes, and ion channels, free radical injury can lead to fatal metabolic and structural derangements. As an example, oxygen radicals injure the sarcolemma and may impair contractile function of the myocyte on this basis [
         <a href="#rid18">
          18
         </a>
         ]. The role for free radicals as a source of significant myocardial damage is further supported by studies showing that free radical scavengers, such as superoxide dismutase, administered during thrombolytic therapy help preserve myocardial function [
         <a href="#rid20">
          20
         </a>
         ]. Finally, reactive oxygen species stimulate leukocyte activation, chemotaxis, and leukocyte-endothelial adherence [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
         Reactive oxygen species may trigger the opening of the mitochondrial permeability transition pore. This is associated with uncoupling of oxidative phosphorylation and the release of pro-apoptotic molecules [
         <a href="#rid21">
          21
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1487.html" rel="external">
          "Myocardial ischemic conditioning: Pathogenesis", section on 'Mediators'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Leukocyte aggregation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Multiple factors induced by ischemia and reperfusion trigger leukocyte aggregation and activation:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Neutrophils are stimulated after plasma membrane phospholipase A2 is activated to form arachidonic acid, which is an important precursor in the inflammation pathway [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cytokines and complement are released from damaged myocardium [
         <a href="#rid22">
          22-24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         New expression of adhesion molecules, diminished release of nitric oxide (NO), and changes in the actin cytoskeleton allow greater vascular permeability, giving neutrophils access to vulnerable myocytes [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Neutrophil accumulation in nonperfused microvessels may contribute to the "no reflow" phenomenon [
         <a href="#rid26">
          26
         </a>
         ]. Once in the extravascular space, leukocytes can release proteases and elastases that destroy the cell membrane and cause cell death [
         <a href="#rid27">
          27,28
         </a>
         ]. However, the roles of the various inflammatory mediators are complex and incompletely understood. Although they play a role in reperfusion injury, some also appear to have cardioprotective effects [
         <a href="#rid23">
          23,24
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Platelet activation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Circulating platelets become activated early during reperfusion, and their degree of activation is related to the duration of preceding ischemia [
         <a href="#rid29">
          29
         </a>
         ]. Furthermore, the degree of platelet activation was related to the extent of reperfusion injury. These observations support the possibility of an important role for activated platelets in reperfusion injury.
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Complement activation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Complement activation appears to play a role in the "no reflow" phenomenon and possibly reperfusion injury [
         <a href="#rid30">
          30
         </a>
         ]. Terminal complement cascade species directly injure the endothelium, rendering it incapable of elaborating vasodilatory compounds such as NO. This perpetuates a cycle of vasoconstriction and reduction in microvascular perfusion, leading to apoptosis not only within the infarct area, but also in the border zone [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Apoptosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Apoptosis, or programmed cell death, has a number of features that distinguish it from necrosis:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Apoptosis can occur in response to limited molecular damage that is otherwise not sufficient to cause a fatal loss of cellular integrity.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Apoptosis is an energy-dependent process.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Apoptosis is an organized sequence of events triggered by specific signals.
        </p>
        <p>
        </p>
        <p>
         While ischemic damage occurs principally through necrosis, reperfusion injury may also act through apoptosis [
         <a href="#rid32">
          32-34
         </a>
         ]. In a rabbit model, markers of apoptosis found in reperfused tissue were not present in normal tissue or tissue injured solely by ischemia [
         <a href="#rid33">
          33
         </a>
         ]. Others have reported the appearance of apoptotic cells in the perinecrotic zone during reperfusion [
         <a href="#rid35">
          35
         </a>
         ] and suggested that understanding the different contributions of necrosis and apoptosis to reperfusion injury may help identify novel treatment strategies [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p>
         A link between reperfusion and apoptosis is supported by studies demonstrating the role of magnesium-dependent superoxide dismutase and oxygen radical formation in the activation of proapoptotic factors. An apoptosis repressor is capable of inhibiting this process and reducing the extent of MI [
         <a href="#rid37">
          37,38
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h1">
          CLINICAL CORRELATES
         </span>
         <span class="headingEndMark">
          —
         </span>
         It has been suggested that reperfusion injury accounts for up to 50 percent of the final myocardial damage in the setting of acute MI [
         <a href="#rid7">
          7
         </a>
         ]. Clinical manifestations of ischemic reperfusion injury include arrhythmias, microvascular dysfunction, myocardial stunning, and myocyte death.
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Arrhythmias
         </span>
         <span class="headingEndMark">
          —
         </span>
         Reperfusion-induced arrhythmias are common in patients treated with thrombolytic therapy, primary percutaneous coronary intervention, and cardiac surgery. The arrhythmia that is most commonly associated with reperfusion is an accelerated idioventricular rhythm. (See
         <a class="medical medical_review" href="/z/d/html/1060.html" rel="external">
          "Ventricular arrhythmias during acute myocardial infarction: Incidence, mechanisms, and clinical features", section on 'Reperfusion arrhythmias'
         </a>
         .)
        </p>
        <p>
         Reperfusion arrhythmias may be mediated by mitochondrial dysfunction. Following prolonged ischemia, the mitochondrion may not be able to restore or maintain its inner membrane potential, thereby destabilizing the action potential and increasing susceptibility to arrhythmias [
         <a href="#rid39">
          39
         </a>
         ]. (See
         <a class="local">
          'Pathophysiology'
         </a>
         above.)
        </p>
        <p>
         Ventricular tachycardia and ventricular fibrillation can also occur after thrombolytic therapy; however, these arrhythmias are more likely to reflect persistent occlusion and infarction than a reperfused infarct-related artery [
         <a href="#rid40">
          40
         </a>
         ]. The pathogenesis of reperfusion arrhythmias is discussed extensively elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/1060.html" rel="external">
          "Ventricular arrhythmias during acute myocardial infarction: Incidence, mechanisms, and clinical features"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Myocardial stunning
         </span>
         <span class="headingEndMark">
          —
         </span>
         Myocardial stunning refers to transient, myocardial dysfunction that occurs after reperfusion, as opposed to dysfunctional hibernating myocardium secondary to ongoing ischemia. It is thought to result from myocardial oxidative stress and calcium overload that continues after reperfusion [
         <a href="#rid41">
          41
         </a>
         ]. Myocardial stunning is also associated with microvascular injury and better levels of regional and global myocardial function are seen when the microvasculature is structurally intact [
         <a href="#rid10">
          10,42-44
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1516.html" rel="external">
          "Pathophysiology of stunned or hibernating myocardium"
         </a>
         .)
        </p>
        <p>
         Because stunning can recover with time, inotropic agents can be used in the short term to improve cardiac function and organ perfusion. Several agents that may prevent its occurrence are being investigated. (See
         <a class="local">
          'Potential therapies'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h2">
          Myocyte death
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most concerning consequence of reperfusion injury is myocyte death. If enough myocytes die, there may be manifestations of acute MI. (See
         <a class="medical medical_review" href="/z/d/html/52.html" rel="external">
          "Diagnosis of acute myocardial infarction"
         </a>
         .)
        </p>
        <p>
         Animal data suggest that up to 50 percent of an infarct size may be attributable to reperfusion injury [
         <a href="#rid45">
          45,46
         </a>
         ]. This observation highlights the potential value of therapies that reduce or eliminate reperfusion injury. Despite an improved understanding of the processes associated with reperfusion injury, there is still uncertainty regarding the magnitude and significance of myocyte death associated with reperfusion.
        </p>
        <p>
         Prolonged ischemia and subsequent reperfusion induce adverse cytosolic and mitochondrial changes, as discussed above. (See
         <a class="local">
          'Pathophysiology'
         </a>
         above.) Opening of the mitochondrial permeability transition pore and irreversible cardiomyocyte hypercontracture precede myocyte death [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h1">
          POTENTIAL THERAPIES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although the pathophysiology of reperfusion injury lends itself to potential therapeutic strategies, no treatment directed at reperfusion injury has been shown to lead to improvement in clinical outcomes. Potential reasons for the ultimate failure of agents that appeared promising in preclinical trials include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Multiple mechanisms contribute to the consequences of MI and reperfusion injury. Thus, the impact of a therapy targeted to a single component of the pathophysiology may be diluted in clinical practice.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Some mechanisms, such as neutrophil stimulation, may be mediators of injury, but also play important roles in the healing process [
         <a href="#rid22">
          22
         </a>
         ]. Targeting such mechanisms would have complex and unpredictable implications on outcomes. (See
         <a class="local">
          'Leukocyte aggregation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         It may not be possible to administer a therapy at the optimal time in clinical practice (eg, some agents may perform best if patients are pretreated).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The presence of comorbidities, such as diabetes, hypercholesterolemia, and age, may impact the efficacy of a new treatment.
        </p>
        <p>
        </p>
        <p>
         Identification of patients at highest risk of reperfusion injury may be an important component of bringing therapies into clinical practice. As an example, myocardial blush grade has been used as a tool to evaluate myocardial level perfusion, and low blush grades correlate with myocardial dysfunction [
         <a href="#rid47">
          47-49
         </a>
         ]. Such tools may also allow for better clinical assessment of therapeutic effectiveness of drugs tested in clinical trials. (See
         <a class="medical medical_review" href="/z/d/html/91.html" rel="external">
          "Diagnosis and management of failed fibrinolysis or threatened reocclusion in acute ST-elevation myocardial infarction", section on 'Primary failure'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H61619977">
         <span class="h2">
          Ischemic conditioning
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ischemic pre- and postconditioning are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/1487.html" rel="external">
          "Myocardial ischemic conditioning: Pathogenesis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1489.html" rel="external">
          "Myocardial ischemic conditioning: Clinical implications"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h2">
          Glycoprotein IIb/IIIa inhibitors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Platelet activation contributes to microvascular injury and reperfusion injury in acute MI [
         <a href="#rid29">
          29
         </a>
         ]. (See
         <a class="local">
          'Platelet activation'
         </a>
         above.) Glycoprotein IIb/IIIa inhibitors are potent inhibitors of platelet activity that improve outcomes in acute MI [
         <a href="#rid50">
          50-53
         </a>
         ]. It is not known if part of the benefit of glycoprotein IIb/IIa inhibitors is due to a reduction in reperfusion injury. (See
         <a class="medical medical_review" href="/z/d/html/81.html" rel="external">
          "Suboptimal reperfusion after primary percutaneous coronary intervention in acute ST-elevation myocardial infarction", section on 'No reflow'
         </a>
         .)
        </p>
        <p>
         In preclinical studies, P2Y
         <sub>
          12
         </sub>
         inhibitors such as
         <a class="drug drug_general" data-topicid="102219" href="/z/d/drug information/102219.html" rel="external">
          cangrelor
         </a>
         significantly ameliorated infarct size when administered prior to the onset of reperfusion, and may have benefits beyond an impact on the rheology of blood. This would indicate pleiotropic effects of these agents beyond their ability to attenuate platelet thrombosis [
         <a href="#rid54">
          54,55
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h2">
          Adenosine
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9359" href="/z/d/drug information/9359.html" rel="external">
          Adenosine
         </a>
         has several properties that make it an attractive candidate to prevent reperfusion injury. These include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         It is a substrate for
         <a class="drug drug_general" data-topicid="9359" href="/z/d/drug information/9359.html" rel="external">
          adenosine
         </a>
         triphosphate (ATP) replenishment
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Vasodilation
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Platelet and neutrophil inhibition
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Direct cardioprotective effect on the cardiomyocyte
        </p>
        <p>
        </p>
        <p>
         Based upon these properties,
         <a class="drug drug_general" data-topicid="9359" href="/z/d/drug information/9359.html" rel="external">
          adenosine
         </a>
         has been tested in both preclinical and clinical studies. The demonstration of cardioprotective effects of adenosine in animal models [
         <a href="#rid56">
          56-58
         </a>
         ] provided the rationale for randomized clinical trials. The following are representative studies that have shown mixed results:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the AMISTAD trial, 236 patients with an acute MI treated with fibrinolysis were randomly assigned to
         <a class="drug drug_general" data-topicid="9359" href="/z/d/drug information/9359.html" rel="external">
          adenosine
         </a>
         or placebo [
         <a href="#rid59">
          59
         </a>
         ]. At a follow-up of six days, infarction size was significantly smaller in patients assigned to adenosine treatment, a benefit that was limited to those with anterior infarctions.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         AMISTAD 2 is the largest trial of intravenous
         <a class="drug drug_general" data-topicid="9359" href="/z/d/drug information/9359.html" rel="external">
          adenosine
         </a>
         as an adjunctive therapy during primary reperfusion for an acute MI [
         <a href="#rid60">
          60,61
         </a>
         ]. This study included 2118 patients treated with primary percutaneous coronary intervention (PCI) or fibrinolytic therapy for anterior ST elevation MI (STEMI). Although infarct size was reduced with adenosine, there was no reduction in a combined clinical end point of heart failure or overall mortality at six months.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the PREVENT-ICARUS trial, 260 patients undergoing elective PCI were randomly assigned to either intracoronary
         <a class="drug drug_general" data-topicid="9359" href="/z/d/drug information/9359.html" rel="external">
          adenosine
         </a>
         or placebo [
         <a href="#rid62">
          62
         </a>
         ]. There was no significant difference between the two groups in the primary end point of a periprocedural increase in troponin I &gt;3 times the upper limit of normal.
        </p>
        <p>
        </p>
        <p>
         In summary, the administration of either intravenous or intracoronary
         <a class="drug drug_general" data-topicid="9359" href="/z/d/drug information/9359.html" rel="external">
          adenosine
         </a>
         has not been established as an effective therapy to reduce the risk of clinical events after PCI in either stable patients or those with acute coronary syndromes. Adequately powered studies to evaluate whether intracoronary adenosine leads to improved clinical outcomes are unlikely to be performed.
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h2">
          Vasodilators
         </span>
         <span class="headingEndMark">
          —
         </span>
         A number of vasodilators have been investigated as potential therapies for reperfusion injury.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Human studies with
         <a class="drug drug_general" data-topicid="9739" href="/z/d/drug information/9739.html" rel="external">
          papaverine
         </a>
         have also demonstrated success in improving angiographically documented TIMI flow grades in epicardial arteries; however, its use is limited by occurrence of ventricular arrhythmias, especially with intracoronary administration [
         <a href="#rid63">
          63
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Several members of the sydnonimine class of nitric oxide (NO) donors have reduced infarct size in an animal model [
         <a href="#rid64">
          64,65
         </a>
         ]. These compounds spontaneously decompose to form NO.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Angiotensin converting enzyme (ACE) inhibitors may have several beneficial actions in reperfusion, including the scavenging of free radicals, vasodilation of the coronary bed, and elevation of prostacyclin and bradykinin levels [
         <a href="#rid66">
          66
         </a>
         ]. In an animal model, ACE inhibitors enhanced coronary blood flow but failed to produce any improvement in regional ventricular function [
         <a href="#rid67">
          67
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Endothelin is a potent vasoconstrictor and possible mediator of the vasospastic component of reperfusion injury. Several studies have investigated the effects of inhibiting endothelin-1 synthesis or blocking its receptor [
         <a href="#rid68">
          68-71
         </a>
         ]. Although conflicting results have been reported, further study is ongoing.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h2">
          Ion channel modulation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Changes in intracellular and extracellular ion concentrations and pH play a role in some of the processes involved in reperfusion injury. Thus, ion channels are an attractive target for novel treatments of reperfusion injury. (See
         <a class="local">
          'Pathophysiology'
         </a>
         above and
         <a class="local">
          'Myocyte hypercontracture'
         </a>
         above.)
        </p>
        <p>
         The potential role of ion channel modulation in the treatment of reperfusion injury is illustrated by the following observations:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sodium/hydrogen (Na/H) exchange inhibition – Na/H exchange is an important regulator of intracellular pH and calcium concentration. Blockade of this exchange reduces calcium uptake and helps to preserve cellular architecture [
         <a href="#rid72">
          72
         </a>
         ]. Several in vitro and animal studies have suggested that inhibition of sodium/hydrogen exchange is effective in reducing reperfusion injury and infarct size [
         <a href="#rid72">
          72-75
         </a>
         ]. However, in a two-stage randomized trial including a total of 1389 patients, the sodium/hydrogen exchange inhibitor eniporide did not improve infarct size or clinical outcome [
         <a href="#rid76">
          76,77
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10262" href="/z/d/drug information/10262.html" rel="external">
          Ranolazine
         </a>
         – Ranolazine is effective in the treatment of chronic angina and may be effective in reperfusion injury and limit infarct size in acute MI [
         <a href="#rid78">
          78
         </a>
         ]. Ranolazine is an inhibitor of the late sodium channel, and via this mechanism, it decreases sodium-dependent intracellular calcium overload during ischemia and reperfusion [
         <a href="#rid79">
          79,80
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1524.html" rel="external">
          "New therapies for angina pectoris", section on 'Ranolazine'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Potassium-ATP (K-ATP) channel openers – K-ATP channels are involved in ischemic preconditioning and microvascular vasodilation. In small clinical trials, K-ATP channel openers, such as nicorandil, resulted in better perfusion and left ventricular wall motion, as well as a reduction in adverse events [
         <a href="#rid81">
          81,82
         </a>
         ]. Cardiac magnetic resonance imaging data suggest that nicorandil may improve microvascular obstruction [
         <a href="#rid83">
          83
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h2">
          Glucose-insulin-potassium solution
         </span>
         <span class="headingEndMark">
          —
         </span>
         Glucose-insulin-potassium therapy has been tested as a potential way to stimulate anaerobic glycolysis, increase ATP levels, and decrease the free fatty acid release. Clinical trials have not demonstrated benefit. (See
         <a class="medical medical_review" href="/z/d/html/68.html" rel="external">
          "Overview of the acute management of non-ST-elevation acute coronary syndromes", section on 'Intravenous glucose-insulin-potassium'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h2">
          Antineutrophil and anticomplement therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Inhibition of the accumulation and activation of neutrophils has been correlated with a reduced infarct size in some studies, although other trials have failed to show a benefit [
         <a href="#rid47">
          47,84-86
         </a>
         ]. Unfortunately, the prolonged time from the onset of infarction to the delivery of antineutrophil therapy such as anti-CD18 antibody may reduce the ability of these agents to mitigate neutrophil-mediated cell injury [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p>
         Similarly disappointing were results reported for the complement inhibitor pexelizumab [
         <a href="#rid87">
          87-89
         </a>
         ]. This may be due to the complexity and the multiple steps of immune activation involved in reperfusion injury. Part of the success of the intracoronary glycoprotein IIb/IIIa inhibitor administration in PCI may be also due to its effect on leukocyte integrin receptors [
         <a href="#rid90">
          90
         </a>
         ]. (See
         <a class="local">
          'Glycoprotein IIb/IIIa inhibitors'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h2">
          Antioxidant therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The prominent role of oxygen radicals in the pathophysiology of reperfusion injury has prompted several studies to evaluate the efficacy of antioxidants in reducing the damage associated with reperfusion. (See
         <a class="local">
          'Oxygen and other free radicals'
         </a>
         above.)
        </p>
        <p>
         The results have been mixed [
         <a href="#rid91">
          91
         </a>
         ], and investigation remains focused at the animal level. Erythropoietin [
         <a href="#rid24">
          24,92-95
         </a>
         ], estrogen [
         <a href="#rid96">
          96,97
         </a>
         ], heme oxygenase1 [
         <a href="#rid98">
          98
         </a>
         ], and hypoxia induced factor–1 [
         <a href="#rid99">
          99
         </a>
         ] have all been shown to reduce reperfusion injury, and investigation is ongoing.
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h2">
          Magnesium
         </span>
         <span class="headingEndMark">
          —
         </span>
         Intravenous magnesium has not been shown to improve outcomes in patients with acute MI. (See
         <a class="medical medical_review" href="/z/d/html/66.html" rel="external">
          "Overview of the acute management of ST-elevation myocardial infarction", section on 'Therapies of unclear benefit'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H25">
         <span class="h2">
          Cyclosporine
         </span>
         <span class="headingEndMark">
          —
         </span>
         Intravenous
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         has not been shown to improve outcomes in patients with STEMI undergoing primary PCI, despite its ability to inhibit the opening of the mitochondrial permeability-transition pore [
         <a href="#rid100">
          100,101
         </a>
         ]. An early study of 58 patients showed that a single intravenous bolus of cyclosporine administered before primary PCI results in a reduction of creatinine kinase by 44 percent, and in a subset of 27 patients, this translated into a 20 percent reduction in infarct size as measured by delayed enhancement cardiac magnetic resonance [
         <a href="#rid102">
          102
         </a>
         ].
        </p>
        <p>
         Despite the promise of benefit from
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         , no benefit has been demonstrated in two clinical trials of STEMI patients undergoing primary PCI.
        </p>
        <p>
         The CIRCUS trial randomly assigned 970 patients to an injection of intravenous
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         or placebo before coronary recanalization [
         <a href="#rid103">
          103
         </a>
         ]. There was no difference between the groups in the primary composite outcome of all-cause death, worsening of heart failure during the initial hospitalization, rehospitalization for heart failure, or adverse left ventricular remodeling at one year (defined as an increase of ≥15 percent in the left ventricular end-diastolic volume). Concerns have been raised that the formulation of cyclosporine used in the study may not have been the best available choice [
         <a href="#rid104">
          104
         </a>
         ].
        </p>
        <p>
         The CYCLE trial randomly assigned 410 patients to intravenous
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         A or placebo prior to primary PCI [
         <a href="#rid105">
          105
         </a>
         ]. There was no difference in the rates of the primary end point (≥70 percent ST-segment resolution 60 minutes after Thrombolysis In Myocardial Infarction flow grade 3)  (
         <a class="graphic graphic_table graphicRef51941" href="/z/d/graphic/51941.html" rel="external">
          table 1
         </a>
         ) or secondary end points of high-sensitivity cardiac troponin T on day four, measures of left ventricular function, or clinical events at six-month follow-up.
        </p>
        <p class="headingAnchor" id="H2737500942">
         <span class="h2">
          Intravenous MTP-131
         </span>
         <span class="headingEndMark">
          —
         </span>
         MTP-131 is a cell-permeable peptide that enhances mitochondrial energetics and improves myocyte survival during reperfusion [
         <a href="#rid21">
          21
         </a>
         ]. (See
         <a class="local">
          'Oxygen and other free radicals'
         </a>
         above.)
        </p>
        <p>
         Reduction in infarct size has been demonstrated with MTP-131 in animal STEMI models [
         <a href="#rid106">
          106
         </a>
         ]. In a Phase 2 trial in which nearly 300 STEMI patients were randomly assigned to intravenous MTP-131 or placebo following successful PCI with stenting, there was no significant difference in infarct size between the two groups [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H12576447">
         <span class="h2">
          Intravenous sodium nitrite
         </span>
         <span class="headingEndMark">
          —
         </span>
         In experimental models,
         <a class="drug drug_general" data-topicid="85782" href="/z/d/drug information/85782.html" rel="external">
          sodium nitrite
         </a>
         reduces ischemic reperfusion injury to the heart. In the NIAMI trial, 229 patients with acute STEMI were randomly assigned to either an intravenous infusion of sodium nitrite or placebo before primary PCI [
         <a href="#rid107">
          107
         </a>
         ]. There was no difference in the two groups with regard to infarct size by cardiac magnetic resonance imaging at six to eight days or six months.
        </p>
        <p class="headingAnchor" id="H444414884">
         <span class="h2">
          Losmapimod
         </span>
         <span class="headingEndMark">
          —
         </span>
         p38 mitogen-activated protein kinase (MAPK) is a stress-activated kinase expressed in the myocardium and endothelial cells that regulates cellular responses, including contraction and death [
         <a href="#rid108">
          108
         </a>
         ]. Losmapimod is an oral inhibitor of p38 MAPK that has been shown to reduce infarct size in preclinical models [
         <a href="#rid109">
          109
         </a>
         ]. In the phase 2 SOLSTICE trial, 535 patients with non-ST elevation MI were randomly assigned to losmapimod or placebo given within 12 hours and continued for 12 weeks [
         <a href="#rid110">
          110
         </a>
         ]. Losmapimod lowered the concentration of circulation inflammatory markers of high-sensitivity C-reactive protein and interleukin 6 within 72 hours and lowered concentrations of brain natriuretic peptide at 12 weeks. No significant difference was seen between the two groups in terms of serious adverse effects.
        </p>
        <p class="headingAnchor" id="H188786638">
         <span class="h2">
          Inhibitors of delta-protein kinase C
         </span>
         <span class="headingEndMark">
          —
         </span>
         Delcasertib is an inhibitor of the delta isoform of protein kinase C. Protein kinase C isoenzymes modulate myocardial protection. (See
         <a class="medical medical_review" href="/z/d/html/1487.html" rel="external">
          "Myocardial ischemic conditioning: Pathogenesis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1487.html" rel="external">
          "Myocardial ischemic conditioning: Pathogenesis", section on 'Protein kinase C'
         </a>
         .).
        </p>
        <p>
         In the PROTECTION AMI trial, 1010 acute MI patients undergoing primary PCI were randomly assigned to one of three doses of delcasertib or placebo given intravenously [
         <a href="#rid111">
          111
         </a>
         ]. There was no difference in infarct size between those who received delcasertib or placebo.
        </p>
        <p class="headingAnchor" id="H29">
         <span class="h2">
          Endovascular cooling
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hypothermia induced before reperfusion in animal models of acute coronary occlusion reduces infarct size. The concept is that myocardial metabolism will be decreased at lower temperatures and thus some cardioprotection will be afforded, analogous to cold cardioplegia used by cardiac surgeons during coronary bypass grafting. Endovascular coils and external cooling blankets have been used to lower core temperature during PCI for acute MI [
         <a href="#rid112">
          112-114
         </a>
         ]. However, the CHILL-MI trial, which used rapid infusion of cold
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         and endovascular cooling prior to PCI, did not reduce the primary end point of infarct size [
         <a href="#rid115">
          115
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H30">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reperfusion injury is an important limitation to the efficacy of primary reperfusion therapies in acute myocardial infarction (MI). Reperfusion injury is characterized by myocardial, vascular, or electrophysiological dysfunction that is induced by the restoration of blood flow to previously ischemic tissue. (See
         <a class="local">
          'Clinical correlates'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The pathophysiology of reperfusion injury is complex, involving abnormalities in energy production and utilization, disturbance of cellular architecture, and possibly leukocyte, platelet, and complement activation. (See
         <a class="local">
          'Pathophysiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reperfusion injury accounts for up to 50 percent of the final myocardial damage in the setting of acute MI. Clinical manifestations of ischemic reperfusion injury include arrhythmias, microvascular dysfunction, myocardial stunning, and myocyte death. (See
         <a class="local">
          'Clinical correlates'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Despite ongoing improvements in the understanding of the underlying mechanisms of reperfusion injury, effective therapies remain elusive. (See
         <a class="local">
          'Potential therapies'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3384390">
         <span class="h1">
          ACKNOWLEDGMENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate staff acknowledges Bernard Gersh, MB, ChB, DPhil, FRCP, MACC, and Duane Pinto, MD, MPH, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Simoons ML, Serruys PW, van den Brand M, et al. Early thrombolysis in acute myocardial infarction: limitation of infarct size and improved survival. J Am Coll Cardiol 1986; 7:717.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           White HD, Norris RM, Brown MA, et al. Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction. N Engl J Med 1987; 317:850.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sheehan FH, Doerr R, Schmidt WG, et al. Early recovery of left ventricular function after thrombolytic therapy for acute myocardial infarction: an important determinant of survival. J Am Coll Cardiol 1988; 12:289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bolli R, Becker L, Gross G, et al. Myocardial protection at a crossroads: the need for translation into clinical therapy. Circ Res 2004; 95:125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cannon RO 3rd. Mechanisms, management and future directions for reperfusion injury after acute myocardial infarction. Nat Clin Pract Cardiovasc Med 2005; 2:88.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ibáñez B, Heusch G, Ovize M, Van de Werf F. Evolving therapies for myocardial ischemia/reperfusion injury. J Am Coll Cardiol 2015; 65:1454.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hausenloy DJ, Erik Bøtker H, Condorelli G, et al. Translating cardioprotection for patient benefit: position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovasc Res 2013; 98:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lønborg JT. Targeting reperfusion injury in the era of primary percutaneous coronary intervention: hope or hype? Heart 2015; 101:1612.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bell RM, Yellon DM. There is more to life than revascularization: therapeutic targeting of myocardial ischemia/reperfusion injury. Cardiovasc Ther 2011; 29:e67.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iliceto S, Galiuto L, Marchese A, et al. Analysis of microvascular integrity, contractile reserve, and myocardial viability after acute myocardial infarction by dobutamine echocardiography and myocardial contrast echocardiography. Am J Cardiol 1996; 77:441.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoffmann R, Haager P, Lepper W, et al. Relation of coronary flow pattern to myocardial blush grade in patients with first acute myocardial infarction. Heart 2003; 89:1147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fernández-Jiménez R, García-Prieto J, Sánchez-González J, et al. Pathophysiology Underlying the Bimodal Edema Phenomenon After Myocardial Ischemia/Reperfusion. J Am Coll Cardiol 2015; 66:816.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ladilov YV, Siegmund B, Balser C, Piper HM. Simulated ischemia increases the susceptibility of rat cardiomyocytes to hypercontracture. Circ Res 1997; 80:69.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meissner A, Morgan JP. Contractile dysfunction and abnormal Ca2+ modulation during postischemic reperfusion in rat heart. Am J Physiol 1995; 268:H100.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ladilov YV, Siegmund B, Piper HM. Protection of reoxygenated cardiomyocytes against hypercontracture by inhibition of Na+/H+ exchange. Am J Physiol 1995; 268:H1531.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piper HM, García-Dorado D, Ovize M. A fresh look at reperfusion injury. Cardiovasc Res 1998; 38:291.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bolli R, Jeroudi MO, Patel BS, et al. Direct evidence that oxygen-derived free radicals contribute to postischemic myocardial dysfunction in the intact dog. Proc Natl Acad Sci U S A 1989; 86:4695.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verma S, Fedak PW, Weisel RD, et al. Fundamentals of reperfusion injury for the clinical cardiologist. Circulation 2002; 105:2332.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Toyokuni S. Reactive oxygen species-induced molecular damage and its application in pathology. Pathol Int 1999; 49:91.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salvemini D, Cuzzocrea S. Superoxide, superoxide dismutase and ischemic injury. Curr Opin Investig Drugs 2002; 3:886.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gibson CM, Giugliano RP, Kloner RA, et al. EMBRACE STEMI study: a Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention. Eur Heart J 2016; 37:1296.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vinten-Johansen J. Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury. Cardiovasc Res 2004; 61:481.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kempf T, Eden M, Strelau J, et al. The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury. Circ Res 2006; 98:351.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Namiuchi S, Kagaya Y, Ohta J, et al. High serum erythropoietin level is associated with smaller infarct size in patients with acute myocardial infarction who undergo successful primary percutaneous coronary intervention. J Am Coll Cardiol 2005; 45:1406.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Becker LC. Myocardial Reperfusion Injury. J Thromb Thrombolysis 1997; 4:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Engler RL, Schmid-Schönbein GW, Pavelec RS. Leukocyte capillary plugging in myocardial ischemia and reperfusion in the dog. Am J Pathol 1983; 111:98.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carden DL, Granger DN. Pathophysiology of ischaemia-reperfusion injury. J Pathol 2000; 190:255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Panés J, Perry M, Granger DN. Leukocyte-endothelial cell adhesion: avenues for therapeutic intervention. Br J Pharmacol 1999; 126:537.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xu Y, Huo Y, Toufektsian MC, et al. Activated platelets contribute importantly to myocardial reperfusion injury. Am J Physiol Heart Circ Physiol 2006; 290:H692.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rezkalla SH, Kloner RA. No-reflow phenomenon. Circulation 2002; 105:656.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saraste A, Pulkki K, Kallajoki M, et al. Apoptosis in human acute myocardial infarction. Circulation 1997; 95:320.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Umansky SR, Cuenco GM, Khutzian SS, et al. Post-ischemic apoptotic death of rat neonatal cardiomyocytes. Cell Death Differ 1995; 2:235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gottlieb RA, Burleson KO, Kloner RA, et al. Reperfusion injury induces apoptosis in rabbit cardiomyocytes. J Clin Invest 1994; 94:1621.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piot CA, Wolfe CL. Apoptosis: A New Mechanism of Lethal Myocardial "Reperfusion Injury"? J Thromb Thrombolysis 1997; 4:67.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhao ZQ, Velez DA, Wang NP, et al. Progressively developed myocardial apoptotic cell death during late phase of reperfusion. Apoptosis 2001; 6:279.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhao ZQ, Vinten-Johansen J. Myocardial apoptosis and ischemic preconditioning. Cardiovasc Res 2002; 55:438.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang YQ, Herman B. ARC protects rat cardiomyocytes against oxidative stress through inhibition of caspase-2 mediated mitochondrial pathway. J Cell Biochem 2006; 99:575.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Donath S, Li P, Willenbockel C, et al. Apoptosis repressor with caspase recruitment domain is required for cardioprotection in response to biomechanical and ischemic stress. Circulation 2006; 113:1203.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Akar FG, Aon MA, Tomaselli GF, O'Rourke B. The mitochondrial origin of postischemic arrhythmias. J Clin Invest 2005; 115:3527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berger PB, Ruocco NA, Ryan TJ, et al. Incidence and significance of ventricular tachycardia and fibrillation in the absence of hypotension or heart failure in acute myocardial infarction treated with recombinant tissue-type plasminogen activator: results from the Thrombolysis in Myocardial Infarction (TIMI) Phase II trial. J Am Coll Cardiol 1993; 22:1773.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bulluck H, Hausenloy DJ. Ischaemic conditioning: are we there yet? Heart 2015; 101:1067.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iliceto S, Galiuto L, Marchese A, et al. Functional role of microvascular integrity in patients with infarct-related artery patency after acute myocardial infarction. Eur Heart J 1997; 18:618.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ito H, Maruyama A, Iwakura K, et al. Clinical implications of the 'no reflow' phenomenon. A predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction. Circulation 1996; 93:223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sabia PJ, Powers ER, Ragosta M, et al. An association between collateral blood flow and myocardial viability in patients with recent myocardial infarction. N Engl J Med 1992; 327:1825.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matsumura K, Jeremy RW, Schaper J, Becker LC. Progression of myocardial necrosis during reperfusion of ischemic myocardium. Circulation 1998; 97:795.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arai M, Lefer DJ, So T, et al. An anti-CD18 antibody limits infarct size and preserves left ventricular function in dogs with ischemia and 48-hour reperfusion. J Am Coll Cardiol 1996; 27:1278.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baran KW, Nguyen M, McKendall GR, et al. Double-blind, randomized trial of an anti-CD18 antibody in conjunction with recombinant tissue plasminogen activator for acute myocardial infarction: limitation of myocardial infarction following thrombolysis in acute myocardial infarction (LIMIT AMI) study. Circulation 2001; 104:2778.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoffmann R, Haager P, Arning J, et al. Usefulness of myocardial blush grade early and late after primary coronary angioplasty for acute myocardial infarction in predicting left ventricular function. Am J Cardiol 2003; 92:1015.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gibson CM, Cannon CP, Murphy SA, et al. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation 2000; 101:125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Montalescot G, Barragan P, Wittenberg O, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001; 344:1895.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neumann FJ, Blasini R, Schmitt C, et al. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation 1998; 98:2695.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Lemos JA, Antman EM, Gibson CM, et al. Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction. Observations from the TIMI 14 trial. Circulation 2000; 101:239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Antoniucci D, Rodriguez A, Hempel A, et al. A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction. J Am Coll Cardiol 2003; 42:1879.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang XM, Liu Y, Cui L, et al. Two classes of anti-platelet drugs reduce anatomical infarct size in monkey hearts. Cardiovasc Drugs Ther 2013; 27:109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bell RM, Sivaraman V, Kunuthur SP, et al. Cardioprotective Properties of the Platelet P2Y12 Receptor Inhibitor, Cangrelor: Protective in Diabetics and Reliant Upon the Presence of Blood. Cardiovasc Drugs Ther 2015; 29:415.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ely SW, Berne RM. Protective effects of adenosine in myocardial ischemia. Circulation 1992; 85:893.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Headrick JP, Hack B, Ashton KJ. Acute adenosinergic cardioprotection in ischemic-reperfused hearts. Am J Physiol Heart Circ Physiol 2003; 285:H1797.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morrison RR, Teng B, Oldenburg PJ, et al. Effects of targeted deletion of A1 adenosine receptors on postischemic cardiac function and expression of adenosine receptor subtypes. Am J Physiol Heart Circ Physiol 2006; 291:H1875.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahaffey KW, Puma JA, Barbagelata NA, et al. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial. J Am Coll Cardiol 1999; 34:1711.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ross AM, Gibbons RJ, Stone GW, et al. A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J Am Coll Cardiol 2005; 45:1775.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kloner RA, Forman MB, Gibbons RJ, et al. Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction: the AMISTAD-2 trial. Eur Heart J 2006; 27:2400.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Luca G, Iorio S, Venegoni L, Marino P. Evaluation of intracoronary adenosine to prevent periprocedural myonecrosis in elective percutaneous coronary intervention (from the PREVENT-ICARUS Trial). Am J Cardiol 2012; 109:202.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ishihara M, Sato H, Tateishi H, et al. Attenuation of the no-reflow phenomenon after coronary angioplasty for acute myocardial infarction with intracoronary papaverine. Am Heart J 1996; 132:959.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siegfried MR, Erhardt J, Rider T, et al. Cardioprotection and attenuation of endothelial dysfunction by organic nitric oxide donors in myocardial ischemia-reperfusion. J Pharmacol Exp Ther 1992; 260:668.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schlüter KD, Weber M, Schraven E, Piper HM. NO donor SIN-1 protects against reoxygenation-induced cardiomyocyte injury by a dual action. Am J Physiol 1994; 267:H1461.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Gilst, WH, Kingma, JH. Protection of the myocardium against postischemic reperfusion damage: possible role of angiotensin-converting enzyme inhibitors. J Cardiovasc Pharmacol 1992; 19:S13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piana RN, Wang SY, Friedman M, Sellke FW. Angiotensin-converting enzyme inhibition preserves endothelium-dependent coronary microvascular responses during short-term ischemia-reperfusion. Circulation 1996; 93:544.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang QD, Li XS, Lundberg JM, Pernow J. Protective effects of non-peptide endothelin receptor antagonist bosentan on myocardial ischaemic and reperfusion injury in the pig. Cardiovasc Res 1995; 29:805.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grover GJ, Dzwonczyk S, Parham CS. The endothelin-1 receptor antagonist BQ-123 reduces infarct size in a canine model of coronary occlusion and reperfusion. Cardiovasc Res 1993; 27:1613.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pernow J, Wang QD. Endothelin in myocardial ischaemia and reperfusion. Cardiovasc Res 1997; 33:518.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Galiuto, L, DeMaria, AN, del Balzo, U, et al. Endothelin A-antagonist reduces no-reflow and infarct size in dogs. J Am Coll Cardiol 1999; Special Issue (Suppl): 382A.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klein HH, Pich S, Bohle RM, et al. Myocardial protection by Na(+)-H+ exchange inhibition in ischemic, reperfused porcine hearts. Circulation 1995; 92:912.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meng HP, Maddaford TG, Pierce GN. Effect of amiloride and selected analogues on postischemic recovery of cardiac contractile function. Am J Physiol 1993; 264:H1831.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hendrikx M, Mubagwa K, Verdonck F, et al. New Na(+)-H+ exchange inhibitor HOE 694 improves postischemic function and high-energy phosphate resynthesis and reduces Ca2+ overload in isolated perfused rabbit heart. Circulation 1994; 89:2787.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rohmann S, Weygandt H, Minck KO. Preischaemic as well as postischaemic application of a Na+/H+ exchange inhibitor reduces infarct size in pigs. Cardiovasc Res 1995; 30:945.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coletta AP, Cleland JG. Clinical trials update: highlights of the scientific sessions of the XXIII Congress of the European Society of Cardiology--WARIS II, ESCAMI, PAFAC, RITZ-1 and TIME. Eur J Heart Fail 2001; 3:747.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zeymer U, Suryapranata H, Monassier JP, et al. The Na(+)/H(+) exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the evaluation of the safety and cardioprotective effects of eniporide in acute myocardial infarction (ESCAMI) trial. J Am Coll Cardiol 2001; 38:1644.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hale SL, Leeka JA, Kloner RA. Improved left ventricular function and reduced necrosis after myocardial ischemia/reperfusion in rabbits treated with ranolazine, an inhibitor of the late sodium channel. J Pharmacol Exp Ther 2006; 318:418.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Antzelevitch C, Belardinelli L, Zygmunt AC, et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 2004; 110:904.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Belardinelli L, Shryock JC, Fraser H. Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine. Heart 2006; 92 Suppl 4:iv6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sakata Y, Kodama K, Ishikura F, et al. Disappearance of the 'no-reflow' phenomenon after adjunctive intracoronary administration of nicorandil in a patient with acute myocardial infarction. Jpn Circ J 1997; 61:455.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ito H, Taniyama Y, Iwakura K, et al. Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction. J Am Coll Cardiol 1999; 33:654.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krombach GA, Higgins CB, Chujo M, Saeed M. Gadomer-enhanced MR imaging in the detection of microvascular obstruction: alleviation with nicorandil therapy. Radiology 2005; 236:510.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gonon AT, Gourine AV, Middelveld RJ, et al. Limitation of infarct size and attenuation of myeloperoxidase activity by an endothelin A receptor antagonist following ischaemia and reperfusion. Basic Res Cardiol 2001; 96:454.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harlan JM, Winn RK. Leukocyte-endothelial interactions: clinical trials of anti-adhesion therapy. Crit Care Med 2002; 30:S214.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Faxon DP, Gibbons RJ, Chronos NA, et al. The effect of blockade of the CD11/CD18 integrin receptor on infarct size in patients with acute myocardial infarction treated with direct angioplasty: the results of the HALT-MI study. J Am Coll Cardiol 2002; 40:1199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahaffey KW, Granger CB, Nicolau JC, et al. Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial. Circulation 2003; 108:1176.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Granger CB, Mahaffey KW, Weaver WD, et al. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. Circulation 2003; 108:1184.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           APEX AMI Investigators, Armstrong PW, Granger CB, et al. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. JAMA 2007; 297:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simon DI, Xu H, Ortlepp S, et al. 7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1. Arterioscler Thromb Vasc Biol 1997; 17:528.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Przyklenk K. Pharmacologic treatment of the stunned myocardium: the concepts and the challenges. Coron Artery Dis 2001; 12:363.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hanlon PR, Fu P, Wright GL, et al. Mechanisms of erythropoietin-mediated cardioprotection during ischemia-reperfusion injury: role of protein kinase C and phosphatidylinositol 3-kinase signaling. FASEB J 2005; 19:1323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bullard AJ, Govewalla P, Yellon DM. Erythropoietin protects the myocardium against reperfusion injury in vitro and in vivo. Basic Res Cardiol 2005; 100:397.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xu B, Dong GH, Liu H, et al. Recombinant human erythropoietin pretreatment attenuates myocardial infarct size: a possible mechanism involves heat shock Protein 70 and attenuation of nuclear factor-kappaB. Ann Clin Lab Sci 2005; 35:161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hirata A, Minamino T, Asanuma H, et al. Erythropoietin just before reperfusion reduces both lethal arrhythmias and infarct size via the phosphatidylinositol-3 kinase-dependent pathway in canine hearts. Cardiovasc Drugs Ther 2005; 19:33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jeanes HL, Wanikiat P, Sharif I, Gray GA. Medroxyprogesterone acetate inhibits the cardioprotective effect of estrogen in experimental ischemia-reperfusion injury. Menopause 2006; 13:80.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sbarouni E, Iliodromitis EK, Bofilis E, et al. Estrogen alone or combined with medroxyprogesterone but not raloxifene reduce myocardial infarct size. Eur J Pharmacol 2003; 467:163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu X, Pachori AS, Ward CA, et al. Heme oxygenase-1 (HO-1) inhibits postmyocardial infarct remodeling and restores ventricular function. FASEB J 2006; 20:207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jung F, Palmer LA, Zhou N, Johns RA. Hypoxic regulation of inducible nitric oxide synthase via hypoxia inducible factor-1 in cardiac myocytes. Circ Res 2000; 86:319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hausenloy DJ, Duchen MR, Yellon DM. Inhibiting mitochondrial permeability transition pore opening at reperfusion protects against ischaemia-reperfusion injury. Cardiovasc Res 2003; 60:617.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ong SB, Samangouei P, Kalkhoran SB, Hausenloy DJ. The mitochondrial permeability transition pore and its role in myocardial ischemia reperfusion injury. J Mol Cell Cardiol 2015; 78:23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piot C, Croisille P, Staat P, et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 2008; 359:473.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cung TT, Morel O, Cayla G, et al. Cyclosporine before PCI in Patients with Acute Myocardial Infarction. N Engl J Med 2015; 373:1021.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hausenloy DJ, Yellon DM. Targeting Myocardial Reperfusion Injury--The Search Continues. N Engl J Med 2015; 373:1073.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ottani F, Latini R, Staszewsky L, et al. Cyclosporine A in Reperfused Myocardial Infarction: The Multicenter, Controlled, Open-Label CYCLE Trial. J Am Coll Cardiol 2016; 67:365.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kloner RA, Hale SL, Dai W, et al. Reduction of ischemia/reperfusion injury with bendavia, a mitochondria-targeting cytoprotective Peptide. J Am Heart Assoc 2012; 1:e001644.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siddiqi N, Neil C, Bruce M, et al. Intravenous sodium nitrite in acute ST-elevation myocardial infarction: a randomized controlled trial (NIAMI). Eur Heart J 2014; 35:1255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marber MS, Rose B, Wang Y. The p38 mitogen-activated protein kinase pathway--a potential target for intervention in infarction, hypertrophy, and heart failure. J Mol Cell Cardiol 2011; 51:485.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ma XL, Kumar S, Gao F, et al. Inhibition of p38 mitogen-activated protein kinase decreases cardiomyocyte apoptosis and improves cardiac function after myocardial ischemia and reperfusion. Circulation 1999; 99:1685.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Newby LK, Marber MS, Melloni C, et al. Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial. Lancet 2014; 384:1187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Direct Inhibition of delta-Protein Kinase C Enzyme to Limit Total Infarct Size in Acute Myocardial Infarction (DELTA MI) Investigators, Bates E, Bode C, et al. Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. Circulation 2008; 117:886.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dixon SR, Whitbourn RJ, Dae MW, et al. Induction of mild systemic hypothermia with endovascular cooling during primary percutaneous coronary intervention for acute myocardial infarction. J Am Coll Cardiol 2002; 40:1928.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ly HQ, Denault A, Dupuis J, et al. A pilot study: the Noninvasive Surface Cooling Thermoregulatory System for Mild Hypothermia Induction in Acute Myocardial Infarction (the NICAMI Study). Am Heart J 2005; 150:933.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kandzari DE, Chu A, Brodie BR, et al. Feasibility of endovascular cooling as an adjunct to primary percutaneous coronary intervention (results of the LOWTEMP pilot study). Am J Cardiol 2004; 93:636.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Erlinge D, Götberg M, Lang I, et al. Rapid endovascular catheter core cooling combined with cold saline as an adjunct to percutaneous coronary intervention for the treatment of acute myocardial infarction. The CHILL-MI trial: a randomized controlled study of the use of central venous catheter core cooling combined with cold saline as an adjunct to percutaneous coronary intervention for the treatment of acute myocardial infarction. J Am Coll Cardiol 2014; 63:1857.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 1511 Version 31.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2937825" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Early thrombolysis in acute myocardial infarction: limitation of infarct size and improved survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2888018" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3392324" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Early recovery of left ventricular function after thrombolytic therapy for acute myocardial infarction: an important determinant of survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15271864" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Myocardial protection at a crossroads: the need for translation into clinical therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16265379" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Mechanisms, management and future directions for reperfusion injury after acute myocardial infarction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25857912" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Evolving therapies for myocardial ischemia/reperfusion injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23334258" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Translating cardioprotection for patient benefit: position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26130664" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Targeting reperfusion injury in the era of primary percutaneous coronary intervention: hope or hype?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20645988" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : There is more to life than revascularization: therapeutic targeting of myocardial ischemia/reperfusion injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8629581" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Analysis of microvascular integrity, contractile reserve, and myocardial viability after acute myocardial infarction by dobutamine echocardiography and myocardial contrast echocardiography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12975402" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Relation of coronary flow pattern to myocardial blush grade in patients with first acute myocardial infarction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26271065" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Pathophysiology Underlying the Bimodal Edema Phenomenon After Myocardial Ischemia/Reperfusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8978324" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Simulated ischemia increases the susceptibility of rat cardiomyocytes to hypercontracture.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7840255" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Contractile dysfunction and abnormal Ca2+ modulation during postischemic reperfusion in rat heart.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7733354" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Protection of reoxygenated cardiomyocytes against hypercontracture by inhibition of Na+/H+ exchange.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9709390" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : A fresh look at reperfusion injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2543984" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Direct evidence that oxygen-derived free radicals contribute to postischemic myocardial dysfunction in the intact dog.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12021216" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Fundamentals of reperfusion injury for the clinical cardiologist.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10355961" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Reactive oxygen species-induced molecular damage and its application in pathology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12137408" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Superoxide, superoxide dismutase and ischemic injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26586786" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : EMBRACE STEMI study: a Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14962479" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16397141" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15862410" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : High serum erythropoietin level is associated with smaller infarct size in patients with acute myocardial infarction who undergo successful primary percutaneous coronary intervention.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10639222" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Myocardial Reperfusion Injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6837725" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Leukocyte capillary plugging in myocardial ischemia and reperfusion in the dog.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10685060" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Pathophysiology of ischaemia-reperfusion injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10188959" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Leukocyte-endothelial cell adhesion: avenues for therapeutic intervention.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16199480" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Activated platelets contribute importantly to myocardial reperfusion injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11827935" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : No-reflow phenomenon.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9008443" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Apoptosis in human acute myocardial infarction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17180028" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Post-ischemic apoptotic death of rat neonatal cardiomyocytes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7929838" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Reperfusion injury induces apoptosis in rabbit cardiomyocytes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10639228" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Apoptosis: A New Mechanism of Lethal Myocardial "Reperfusion Injury"?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11445670" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Progressively developed myocardial apoptotic cell death during late phase of reperfusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12160941" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Myocardial apoptosis and ischemic preconditioning.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16639714" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : ARC protects rat cardiomyocytes against oxidative stress through inhibition of caspase-2 mediated mitochondrial pathway.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16505176" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Apoptosis repressor with caspase recruitment domain is required for cardioprotection in response to biomechanical and ischemic stress.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16284648" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : The mitochondrial origin of postischemic arrhythmias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8245327" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Incidence and significance of ventricular tachycardia and fibrillation in the absence of hypotension or heart failure in acute myocardial infarction treated with recombinant tissue-type plasminogen activator: results from the Thrombolysis in Myocardial Infarction (TIMI) Phase II trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25887783" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Ischaemic conditioning: are we there yet?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9129892" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Functional role of microvascular integrity in patients with infarct-related artery patency after acute myocardial infarction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8548892" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Clinical implications of the 'no reflow' phenomenon. A predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1448120" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : An association between collateral blood flow and myocardial viability in patients with recent myocardial infarction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9498544" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Progression of myocardial necrosis during reperfusion of ischemic myocardium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8609356" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : An anti-CD18 antibody limits infarct size and preserves left ventricular function in dogs with ischemia and 48-hour reperfusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11733394" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Double-blind, randomized trial of an anti-CD18 antibody in conjunction with recombinant tissue plasminogen activator for acute myocardial infarction: limitation of myocardial infarction following thrombolysis in acute myocardial infarction (LIMIT AMI) study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14583349" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Usefulness of myocardial blush grade early and late after primary coronary angioplasty for acute myocardial infarction in predicting left ventricular function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10637197" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11419426" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9851955" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10645918" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction. Observations from the TIMI 14 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14662245" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23318690" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Two classes of anti-platelet drugs reduce anatomical infarct size in monkey hearts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26179955" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Cardioprotective Properties of the Platelet P2Y12 Receptor Inhibitor, Cangrelor: Protective in Diabetics and Reliant Upon the Presence of Blood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1537125" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Protective effects of adenosine in myocardial ischemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14561676" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Acute adenosinergic cardioprotection in ischemic-reperfused hearts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16679400" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Effects of targeted deletion of A1 adenosine receptors on postischemic cardiac function and expression of adenosine receptor subtypes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10577561" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15936605" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16782719" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction: the AMISTAD-2 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22000773" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Evaluation of intracoronary adenosine to prevent periprocedural myonecrosis in elective percutaneous coronary intervention (from the PREVENT-ICARUS Trial).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8892767" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Attenuation of the no-reflow phenomenon after coronary angioplasty for acute myocardial infarction with intracoronary papaverine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1738117" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Cardioprotection and attenuation of endothelial dysfunction by organic nitric oxide donors in myocardial ischemia-reperfusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7943392" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : NO donor SIN-1 protects against reoxygenation-induced cardiomyocyte injury by a dual action.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Protection of the myocardium against postischemic reperfusion damage: possible role of angiotensin-converting enzyme inhibitors
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8565174" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Angiotensin-converting enzyme inhibition preserves endothelium-dependent coronary microvascular responses during short-term ischemia-reperfusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7656284" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Protective effects of non-peptide endothelin receptor antagonist bosentan on myocardial ischaemic and reperfusion injury in the pig.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8287438" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : The endothelin-1 receptor antagonist BQ-123 reduces infarct size in a canine model of coronary occlusion and reperfusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9093521" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Endothelin in myocardial ischaemia and reperfusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Endothelin A-antagonist reduces no-reflow and infarct size in dogs
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7641374" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Myocardial protection by Na(+)-H+ exchange inhibition in ischemic, reperfused porcine hearts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8391755" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Effect of amiloride and selected analogues on postischemic recovery of cardiac contractile function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8205693" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : New Na(+)-H+ exchange inhibitor HOE 694 improves postischemic function and high-energy phosphate resynthesis and reduces Ca2+ overload in isolated perfused rabbit heart.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8746210" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Preischaemic as well as postischaemic application of a Na+/H+ exchange inhibitor reduces infarct size in pigs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11738228" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Clinical trials update: highlights of the scientific sessions of the XXIII Congress of the European Society of Cardiology--WARIS II, ESCAMI, PAFAC, RITZ-1 and TIME.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11704395" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : The Na(+)/H(+) exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the evaluation of the safety and cardioprotective effects of eniporide in acute myocardial infarction (ESCAMI) trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16617168" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Improved left ventricular function and reduced necrosis after myocardial ischemia/reperfusion in rabbits treated with ranolazine, an inhibitor of the late sodium channel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15302796" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16775092" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9192246" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Disappearance of the 'no-reflow' phenomenon after adjunctive intracoronary administration of nicorandil in a patient with acute myocardial infarction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10080465" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16040908" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Gadomer-enhanced MR imaging in the detection of microvascular obstruction: alleviation with nicorandil therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11605992" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Limitation of infarct size and attenuation of myeloperoxidase activity by an endothelin A receptor antagonist following ischaemia and reperfusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12004238" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Leukocyte-endothelial interactions: clinical trials of anti-adhesion therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12383565" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : The effect of blockade of the CD11/CD18 integrin receptor on infarct size in patients with acute myocardial infarction treated with direct angioplasty: the results of the HALT-MI study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12925455" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12925454" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17200474" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9102172" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : 7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11491201" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Pharmacologic treatment of the stunned myocardium: the concepts and the challenges.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15946993" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Mechanisms of erythropoietin-mediated cardioprotection during ischemia-reperfusion injury: role of protein kinase C and phosphatidylinositol 3-kinase signaling.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15944807" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Erythropoietin protects the myocardium against reperfusion injury in vitro and in vivo.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15943180" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Recombinant human erythropoietin pretreatment attenuates myocardial infarct size: a possible mechanism involves heat shock Protein 70 and attenuation of nuclear factor-kappaB.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15883754" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Erythropoietin just before reperfusion reduces both lethal arrhythmias and infarct size via the phosphatidylinositol-3 kinase-dependent pathway in canine hearts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16607102" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Medroxyprogesterone acetate inhibits the cardioprotective effect of estrogen in experimental ischemia-reperfusion injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12706470" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Estrogen alone or combined with medroxyprogesterone but not raloxifene reduce myocardial infarct size.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16449792" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Heme oxygenase-1 (HO-1) inhibits postmyocardial infarct remodeling and restores ventricular function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10679484" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Hypoxic regulation of inducible nitric oxide synthase via hypoxia inducible factor-1 in cardiac myocytes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14659807" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Inhibiting mitochondrial permeability transition pore opening at reperfusion protects against ischaemia-reperfusion injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25446182" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : The mitochondrial permeability transition pore and its role in myocardial ischemia reperfusion injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18669426" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Effect of cyclosporine on reperfusion injury in acute myocardial infarction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26321103" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Cyclosporine before PCI in Patients with Acute Myocardial Infarction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26321104" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Targeting Myocardial Reperfusion Injury--The Search Continues.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26821623" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Cyclosporine A in Reperfused Myocardial Infarction: The Multicenter, Controlled, Open-Label CYCLE Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23130143" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Reduction of ischemia/reperfusion injury with bendavia, a mitochondria-targeting cytoprotective Peptide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24639423" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Intravenous sodium nitrite in acute ST-elevation myocardial infarction: a randomized controlled trial (NIAMI).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21062627" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : The p38 mitogen-activated protein kinase pathway--a potential target for intervention in infarction, hypertrophy, and heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10190877" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Inhibition of p38 mitogen-activated protein kinase decreases cardiomyocyte apoptosis and improves cardiac function after myocardial ischemia and reperfusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24930728" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18250271" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12475451" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Induction of mild systemic hypothermia with endovascular cooling during primary percutaneous coronary intervention for acute myocardial infarction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16290966" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : A pilot study: the Noninvasive Surface Cooling Thermoregulatory System for Mild Hypothermia Induction in Acute Myocardial Infarction (the NICAMI Study).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14996598" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Feasibility of endovascular cooling as an adjunct to primary percutaneous coronary intervention (results of the LOWTEMP pilot study).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24509284" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Rapid endovascular catheter core cooling combined with cold saline as an adjunct to percutaneous coronary intervention for the treatment of acute myocardial infarction. The CHILL-MI trial: a randomized controlled study of the use of central venous catheter core cooling combined with cold saline as an adjunct to percutaneous coronary intervention for the treatment of acute myocardial infarction.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
